PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Go online to PeerView.com/VTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for bladder cancer has rapidly evolved. The largely chemotherapy-based approaches of the past are giving way to the use of immune checkpoint inhibitors, targeted agents, and antibody–drug conjugates in advanced disease, as well as bladder-sparing and perioperative approaches in early-stage disease settings. How can oncology nurses synthesize the diverse body of clinical evidence on approved and emerging strategies into the realities of real-world cancer care to successfully address the therapeutic and educational needs of patients across the disease continuum? To help nurses rise to the challenge of modern bladder cancer management, this PeerView activity, based on a recent live event and developed in collaboration with the Bladder Cancer Advocacy Network, features an interprofessional expert panel that provides overview of the rationale and clinical evidence supporting the use of targeted, immunotherapeutic, and antibody-based strategies in bladder cancer. The panel also offers in-depth guidance on safe and effective integration of guideline-recommended therapies into personalized patient care and strategies to mitigate and manage adverse reactions and effectively support patients. Upon completion of this activity, participants should be better able to: Summarize new evidence on therapeutic strategies for bladder cancer management based on innovative drug delivery approaches, modern immunotherapy regimens, and targeted agents across the disease continuum; Develop educational strategies related to therapeutic expectations and safety considerations to enhance quality of life for patients with varying stages of bladder cancer; and Incorporate evidence- and team-based management and nursing protocols to address the unique suite of adverse events associated with approved and emerging therapeutics for bladder cancer

Go online to PeerView.com/UNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this discussion-based activity, two experts on ovarian cancer discuss the role of PARP inhibitors in treating advanced ovarian cancer. Upon completion of this activity, participants should be better able to: Adapt workflows to ensure that patients with ovarian cancer are receiving timely and appropriate genetic testing for BRCA, HRD, and other mutations that can help determine the role of PARP inhibitor therapy; Cite current efficacy and safety evidence on PARP inhibitors in different populations of patients with ovarian cancer; Utilize PARP inhibitors in the appropriate management of patients with ovarian cancer, including within the context of clinical trials, in accordance with current clinical evidence, guideline recommendations, mutation status, and patient needs and preferences; and Employ collaborative strategies to recognize and manage adverse events related to PARP inhibitor use in patients with ovarian cancer

Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

Go online to PeerView.com/JPU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Observed differences in healthcare disparities for patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) have led to the recognition of racial and ethnic minorities as an independent predictor of worse disease outcomes in SLE/LN. Earlier diagnosis, earlier intervention, treatment strategies targeted to clinical remission or low disease activity, and effective communication and collaboration between providers and patients could offer the opportunity to reduce damage, thus improving long-term outcomes. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Drs. Sheikh and Rovin will explore the emerging concept of treat to target, as well as the use of currently available and new/emerging biologic therapies, along with strategies to help learners optimize treatment for patients with SLE/LN. Upon completion of this activity, participants should be better able to: Diagnose SLE, including LN, as early as possible in the course of disease to prevent organ damage and initiate appropriate therapy; Monitor disease activity and response to treatment in SLE and LN based on individual patient needs; Select appropriate treatment for SLE and LN to reduce disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life; and Deliver patient-centered and culturally competent care to improve management of symptoms and promote adherence to long-term treatment in patients with SLE and LN.

Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

Go online to PeerView.com/PNF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. “Treatment intensification”—or the use of combination treatment strategies—has now become the standard of care for patients with metastatic hormone-sensitive prostate cancer. Shown to extend overall survival beyond single-agent treatment, these combinations of androgen deprivation therapy and other effective treatments such as docetaxel chemotherapy and/or novel androgen axis inhibitors have resulted in regulatory approvals and updates to clinical practice guidelines. Given the range of effective options and more on the horizon, as additional agents and combinations are also being studied in localized and advanced disease, how do clinicians ensure that the right patients are getting the right treatments? In this activity, based on a recent live symposium, expert faculty pair in-depth updates on efficacy and safety data on approved and emerging regimens with case-based discussion of best practices for bringing treatment advances to the clinic. Featured topics include individualizing care based on patient-, disease-, and treatment-related factors, toxicity management, and patient perspectives. Upon completion of this activity, participants should be better able to: Summarize the rationale and clinical evidence for established and emerging hormonal therapeutic approaches for patients with prostate cancer; Employ optimal, individualized treatment plans for patients with prostate cancer that incorporate established and emerging hormonal therapeutics, as appropriate, taking into consideration individual patient-, disease-, and treatment-related factors; and Apply evidence- and team-based strategies to proactively mitigate and manage treatment-related adverse events that may occur in patients with prostate cancer who are receiving established and emerging hormonal therapeutics as part of their care.

Go online to PeerView.com/FFQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the number of approved treatment strategies in renal cell carcinoma (RCC) grows, there are new opportunities to provide personalized medicine to patients in a variety of settings. Multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) are now options in the frontline treatment of advanced disease, while recent data also show that immunotherapy-based combinations may improve survival in patient subpopulations with poor prognostic features. In this activity, based on a recent live symposium, a panel of experts reviews the latest efficacy and safety evidence for approved and emerging strategies for the treatment of patients with advanced RCC in the frontline and refractory settings and engages in discussions of relevant patient cases that will provide insight on bringing these therapeutic advances into the clinic. Featured topics include treatment selection and sequencing and addressing potential therapy-related toxicities. Upon completion of this activity, participants should be better able to: Assess treatment efficacy and safety of established and emerging therapies for patients with RCC; Design personalized treatments incorporating approved and emerging therapies utilizing current evidence and patient-, disease-, and treatment-specific factors for patients with RCC; and Develop best practices and evidence-based strategies to anticipate, mitigate, and manage various adverse events associated with modern treatments for patients with RCC.

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer’s disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer’s disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/FSW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore new horizons in complement-targeted treatments with two leading experts who share fresh insights into the underlying pathophysiology of complement-associated kidney diseases and provide evidence-based guidance on their diagnosis and treatment. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of complement-associated kidney diseases, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets; Differentially diagnose patients with complement-associated kidney diseases in a timely manner using evidence-based tools and strategies; and Describe current and emerging treatments for complement-associated kidney diseases, including data from recent clinical trials.

Go online to PeerView.com/TCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients who have severe asthma with uncontrolled symptoms and exacerbations are at risk of losing lung function over time. Research and treatment over the past several years have focused on the downstream effectors of allergic and eosinophilic inflammation, including IgE, sputum and blood eosinophils, and IL-4, IL-5, and IL-13. However, the immunology of the epithelial alarmin TSLP provides an opportunity for a novel approach to treat asthma inflammation. In this activity, based on a recent live symposium, experts apply evidence-based guidelines and translate new data to treat their patients with severe asthma effectively, with a goal of reducing and preventing disease progression (eg, airway remodeling) and preserving quality of life. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting the airway epithelium in the treatment of severe, uncontrolled asthma; Apply recent pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe, uncontrolled asthma; and Select individualized treatment for patients with severe, uncontrolled asthma based on various factors, including the latest clinical evidence, without dependency on biomarker status